Serum Institute of India Ltd

Serum Institute of India From Wikipedia, the free encyclopedia Jump to navigationJump to search This article may be expanded with text translated from the corresponding article in Finnish. (May 2020) Click [show] for important translation instructions. Serum Institute of India Private Limited Serum Institute of India logo.svg Founder Cyrus S. Poonawalla Headquarters Pune, India Key people Adar Poonawalla (President) Revenue Increase US$595 million (2015) Net income Increase US$295 million (2015) Website www.seruminstitute.com/ Edit this on Wikidata Serum Institute of India is a manufacturer of immunobiological drugs including vaccines in India.[1][2] It was founded by Cyrus Poonawalla in 1966.[3] The company is the world's largest vaccine producer by number of doses produced.[4] It is currently developing an intra-nasal swine flu vaccine.[5] In 2016, with support from US-based Mass Biologics of the University of Massachusetts Medical School, it invented a fast-acting anti-rabies agent, Rabies Human Monoclonal Antibody (RMAb), also known as Rabishield.[6] In March 2020, the company started manufacturing COVID-19 vaccine for some strains of COVID-19 virus, created by the Jenner Institute at Oxford University.[7] References "Serum Institute of India Pvt. Ltd.: Private Company Information". bloomberg.com. Retrieved 30 September 2018. "SERUM INSTITUTE OF INDIA PRIVATE LIMITED - Company, directors and contact details". zaubacorp.com. Retrieved 30 September 2018. "About Us". Serum Institute of India. Retrieved 8 December 2016. "Cyrus Poonawalla on Forbes Lists". Forbes. Retrieved 24 March 2015. "'India developing indigenous swine flu vaccine'". The Times of India. Retrieved 1 February 2015. "Fast-acting anti-rabies drug set for India launch - Times of India". The Times of India. Retrieved 12 June 2016. "An Indian firm starts mass-producing an unproven covid-19 vaccine". The Economist. Retrieved 28 April 2020.